Arzneimittelforschung 2007; 57(6): 347-351
DOI: 10.1055/s-0031-1296629
Antibiotics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Pharmacokinetics and Bioequivalence Study of Doxycycline Capsules in Healthy Male Subjects

Michael H. Gschwend
1   Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Wolfgang Martin
1   Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Aydin Erenmemişoğlu
2   DEKAM-IKU Good Clinical Practices Center, Erciyes University, Medical School, Kayseri, Turkey
,
Margit Scherm
3   AAI GmbH & Co KG, Neu-Ulm, Germany
,
Carmen Dilger
3   AAI GmbH & Co KG, Neu-Ulm, Germany
,
Uygur Tamur
4   DEVA Holding A.Ş., 4. Levent, Istanbul, Turkey
,
Ilker Kanzik
5   IDE Pharmaceutical Consulting, Ankara, Turkey
6   Gazi University Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey
,
A. Atilla Hincal
5   IDE Pharmaceutical Consulting, Ankara, Turkey
7   Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Sihhiye, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2011 (online)

Abstract

The aim of the present study was to compare the bioavailability of doxycycline (CAS 564-25-0) from two different doxycycline hyclate (CAS 24390-14-5) capsules (Monodoks© 100 mg capsule as test preparation and 100 mg capsule of the originator product as reference preparation) in 24 healthy male subjects. The study was conducted according to an open-label, randomised two-period cross-over design with a wash-out phase of 16 days. Blood samples for pharmacokinetic profiling were taken up to 72 h post-dose, and doxycycline plasma concentrations were determined with a validated HPLC method with UV-detection. Maximum plasma concentrations (Cmax) of 1,715.1 ng/ml (test) and 1,613.3 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC0→∞)of 28,586.5 ng · h/ml (test) and 29,047.5 ng · h/ml (reference) were calculated. The median tmax was 1.88 h (test) and 2.00 h (reference). Plasma elimination half-lives (t1/2) of 16.49 h (test) and 16.75 h (reference) were determined. Both primary target parameters AUC0→∞ and Cmax were tested parametrically by analysis of variance (ANOVA) and the 90% confidence intervals were between 92.39%-l03.53% (AUC0→∞) and 98.45%-111.74% (Cmax). Bioequivalence betweer test and reference preparation was demonstrated since for both parameters AUC and Cmax the 90% confidence intervals of the T/R ratios of logarithmically transformed data were in the generally accepted range of 80%-l25 %.